SciBase Completes Directed Share Issue
On a recent announcement, SciBase Holding AB (publ) detailed the successful completion of a directed share issue, enabling their partnership with Castle Biosciences, Inc. This strategic move was authorized during a recent annual general meeting and is expected to fortify SciBase’s financial standing and enhance its innovative capabilities in the medical technology sector.
Details of the Directed Share Issue
The directed share issue was executed with deviations from the preferential rights of existing shareholders, culminating in an impressive raise of approximately SEK 19 million. The subscription price was set at SEK 0.40 per share. The transaction hinged on the approval from the Swedish Inspectorate of Strategic Products (ISP), which confirmed that the application would not face any action, enabling all shares in the directed issue to be subscribed.
Allocation of Shares
Following the ISP's notification, the Board of Directors resolved to allocate all shares involved in this directed issue to Castle Biosciences. This allocation not only highlights the trust and partnership between the two firms but is also an important step for SciBase in securing its financial future.
Impact on Share Capital
As a direct consequence of this directed issue, SciBase will see a notable increase in its share capital by SEK 2,394,347.50 through the issuance of 47,886,950 new shares. However, this also results in a dilution of approximately 11.6 percent for the existing shareholders of the company.
Role of Advisors
To navigate this complex transaction, SciBase engaged Vator Securities as its financial advisor and Advokatfirman Schjødt as the legal advisor. Their expertise was crucial in facilitating the directed share issue and ensuring smooth compliance with all regulatory requirements.
About SciBase
SciBase is a pioneering global medical technology company that specializes in early detection and prevention of skin diseases. Through their innovative product Nevisense, the company combines advanced AI technology with electrodermal impedance spectroscopy to enhance diagnostic accuracy in dermatology.
With over 20 years of research foundations from Karolinska Institutet, SciBase remains a leader in dermatological advancements. The company's mission emphasizes reducing patient suffering and facilitating doctors in improving lives through timely diagnostics.
Listing Information
Since being listed on the Nasdaq First North Growth Market, SciBase has actively communicated its milestones and progress to investors and stakeholders. The company continues to focus on expanding its market presence and refining its diagnostic tools.
Frequently Asked Questions
What does the directed share issue entail?
The directed share issue involves SciBase issuing approximately SEK 19 million worth of shares to Castle Biosciences, which will aid in advancing their medical technology efforts.
Who advised SciBase during the share issue?
SciBase was advised by Vator Securities for financial matters and Advokatfirman Schjødt for legal advice throughout the directed share issue process.
How will the share capital be affected by this issue?
The share capital of SciBase will increase by SEK 2,394,347.50 with the issuance of 47,886,950 new shares, but this does create a dilution for existing shareholders.
What is the strategic significance of this deal?
This partnership not only strengthens SciBase's financial base but also enhances its capacity to innovate and deliver on its mission of improving skin disease diagnostics.
What is the role of Castle Biosciences in this issue?
Castle Biosciences is the recipient of the shares issued in the directed share issue and is likely to collaborate with SciBase to enhance technologies related to dermatological diagnostics.
